Document is current
Any future updates will be listed below
-
Authors
Commereuc, Morgane
Nevoret, Camille
Radermacher, Peter
Katsahian, Sandrine
Asfar, Pierre
Schortgen, Frédérique https://orcid.org/0000-0003-1756-7508
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01722422 at ClinicalTrials.govDocuments that mention this clinical trial
Hyperchloremia is not associated with AKI or death in septic shock patients: results of a post hoc analysis of the “HYPER2S” trial
https://doi.org/10.1186/s13613-019-0570-3
- License Information
-
More Information
Article History
Received: 8 May 2019
Accepted: 13 August 2019
First Online: 22 August 2019
Ethics approval and consent to participate
: For all participating centres, the “HYPER2S” trial was approved by the ethics committee of “Ouest II Angers” in the date of 17/07/2012. Written informed consent was obtained from all patients, their next of kin, or another surrogate decision maker, as appropriate.
: Not applicable.
: MC, CN, PR, SK, FS declare that they have no competing interests. PA declares that: he had performed an expertise for the government agency of “Banque Publique d’Investissement”, he had received support from LFB for travels to two medical conferences.
